Endometrial Cancer News and Research

RSS

Premier, Xoft execute group purchasing contract

Premier Inc., an alliance of more than 2,300 U.S. hospitals and 67,000-plus other healthcare sites working together to achieve high quality, cost-effective care, and Xoft, Inc., the leading provider of FDA-cleared Electronic Brachytherapy Systems, announced the execution of a group purchasing contract. Xoft was awarded an exclusive three-year contract for brachytherapy systems with Premier Purchasing Partners L.P., the group purchasing unit of Premier, Inc.

15 Jul 2010

OvaGene Oncology completes license agreements with key Norwegian cancer researchers

OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today that it has completed license agreements with key Norwegian cancer researchers. The agreements allow OvaGene to validate two new promising genomic technologies with the intention of developing these into clinical laboratory tests.

13 Jul 2010

MiCK assay effective in predicting best chemotherapy response for Endometrial Cancer patients: Study

Oncologists working with DiaTech Oncology have published the results of a comprehensive study to determine the effectiveness of the Microculture Kinetic (MiCK) assay for apoptosis in predicting the best chemotherapy response for Endometrial Cancer patients. (Journal of Gynecologic Oncology March 2010 Mar)

12 Jul 2010

ESMO releases revised set of clinical guidelines for cancer patient care

The European Society for Medical Oncology just released an enhanced and revised set of clinical recommendations designed to help oncologists deliver the best quality care to their patients.

8 Jul 2010

Aeterna Zentaris, Almac collaborate on study of AEZS-108 doxorubicin LHRH targeted conjugate compound

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced a collaborative study with Almac's Diagnostics division for the Company's doxorubicin luteinizing hormone-releasing hormone (LHRH) targeted conjugate compound, AEZS-108, aimed at determining LHRH receptor expression through the development of a companion diagnostic tool.

28 Jun 2010

Xoft reports clinical benefits of isotope-free electronic radiation therapy for treatment of cancer

The clinical benefits of isotope-free electronic radiation therapy delivered directly to cancer sites with minimal exposure to surrounding healthy tissue continues to be substantiated by multiple publications, according to Xoft, Inc., developer of the Axxent Electronic Brachytherapy, eBx System. The leading provider of FDA-cleared Electronic Brachytherapy Systems, Xoft provides systems for single-dose intraoperative radiation therapy and accelerated brachytherapy applications.

15 Jun 2010

University of Missouri researchers to investigate cadmium's potential for causing endometrial cancer

McDonald's announced a recall recently of 12 million "Shrek"-themed collectible glasses because traces of the toxic metal cadmium were found in them. Cadmium, a silver-white metal, is found in many substances, including certain foods and batteries, and experts believe that it might be a carcinogen. In a new study, University of Missouri researchers will investigate cadmium's potential for causing endometrial cancer.

10 Jun 2010

Interim data from multiple ongoing trials of XL147 PI3K inhibitor to be presented at ASCO 2010

Exelixis, Inc. today reported updated interim data from three ongoing trials of XL147 (SAR245408), a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

8 Jun 2010

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it presented positive efficacy and safety data for its doxorubicin targeted conjugate compound, AEZS-108, in ovarian cancer.

7 Jun 2010

COMMD1 protein restrains metastatic potential of invasive cancer cell line: Researchers

Researchers at UT Southwestern Medical Center have determined that cancer cells lacking a key protein are more invasive and more likely to metastasize, providing a possible drug target to combat certain tumor types.

5 Jun 2010

152 research and training grants awarded to researchers at 93 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 152 new national research and training grants totaling $50,717,000 in the first of two grants cycles for 2010. The grants, primarily to early career researchers, cover a broad range of investigator-initiated ideas at 93 institutions nationwide, from whether cadmium exposure increases the risk of endometrial cancer, to studies of plant and bacterial-bourne compounds, to a study on a protein called survivin that could lead to novel drugs targeting prostate cancer.

18 May 2010

Aeterna Zentaris' AEZS-108 receives orphan medicinal product designation for ovarian cancer in Europe

Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency, for its compound AEZS-108 for the treatment of ovarian cancer. AEZS-108, the Company's doxorubicin targeted conjugate compound, is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

17 May 2010

FDA approves Aeterna Zentaris' AEZS-108 IND for bladder cancer

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its doxorubicin targeted conjugate compound, AEZS-108, in luteinizing hormone releasing hormone (LHRH) receptor positive urothelial (bladder) cancer.

12 May 2010

Exelixis first-quarter revenues increase to $42.2 million

Exelixis, Inc. today reported financial results for the first quarter ended March 31, 2010.

12 May 2010

Aeterna Zentaris granted FDA orphan-drug designation for AEZS-108 in ovarian cancer

Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrinology, today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate compound, for the treatment of ovarian cancer. AEZS-108 is currently in a Phase 2 trial in advanced ovarian and advanced endometrial cancer in Europe.

6 May 2010

RayBiotech announces biomarker grant winners

RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."

6 May 2010

Waxman Foundation honors molecular biologist Alan Ashworth with the David T. Workman Memorial Award

Molecular biologist Alan Ashworth, Ph.D., FRS, the director of the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research in London will receive the David T. Workman Memorial Award on May 17. The two-year grant of $50,000 from the Samuel Waxman Cancer Research Foundation will support Dr. Ashworth's work with PARP inhibitors in BRCA-mutated cancers.

23 Apr 2010

Raloxifene, tamoxifen remain effective options in prevention of breast cancer, finds 19,490-patient study

In an update of the 19,490-patient Study of Tamoxifen and Raloxifene (STAR) P-2 trial in breast cancer prevention, both raloxifene and tamoxifen remain effective options to prevent breast cancer at 81 months of follow-up.

19 Apr 2010

Æterna Zentaris announces 2009 financial and operating results

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the fourth quarter and the full year ended December 31, 2009.

24 Mar 2010

Combination of gemcitabine and cisplatin limits the progression of endometrial cancer: Study

Researchers from The University of Texas M. D. Anderson Cancer Center report that in a small study of women with advanced or recurrent endometrial cancer, gemcitabine and cisplatin, when used in combination, produced a response rate in fifty percent of patients.

18 Mar 2010